Related Experiment Video
Updated: Jul 4, 2025
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Evolving standards and future directions for systemic therapies in cervical cancer
Daniel Jia Ming Ang1, Jack Junjie Chan1,2
1Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
Abstract:
Several groundbreaking clinical trials with the potential to transform the management paradigm of both locally advanced and persistent, recurrent, or metastatic cervical cancers have been presented in 2023. This review describes the reported data from INTERLACE and KEYNOTE-A18 in the locally advanced setting, as well as BEATcc, innovaTV 301 and DESTINY-PanTumor02 for advanced disease. The practice implications of their positive results are interpreted in the context of global health considerations, and updated treatment algorithms are proposed. Furthermore, emerging trends in drug development for cervical cancer are discussed. As the routine use of immune checkpoint inhibitors (ICIs) for curative and palliative indications increases in the foreseeable future, patients whose cervical cancers which persist, relapse or progress after prior ICI exposure will represent an area of unmet clinical need and form the key target population for next-generation trials. Future research will help shape oncologists' approaches in the optimal selection, sequencing and re-treatment or rechallenge of immuno-oncology agents and/or antibody-drug conjugates in women with cervical cancer.
Insights
Groundbreaking 2023 clinical trials offer new hope for cervical cancer patients. New data from INTERLACE, KEYNOTE-A18, BEATcc, innovaTV 301, and DESTINY-PanTumor02 are reshaping treatment for advanced and recurrent disease.
Area of Science:
- Oncology
- Clinical Trials
- Cancer Therapeutics
Background:
- Significant advancements in cervical cancer treatment emerged in 2023.
- Focus on locally advanced and persistent, recurrent, or metastatic disease settings.
Purpose of the Study:
- To review pivotal 2023 clinical trial data for cervical cancer.
- Interpret practice implications and propose updated treatment algorithms.
- Discuss emerging drug development trends and future research directions.
Main Methods:
- Analysis of data from key trials: INTERLACE, KEYNOTE-A18, BEATcc, innovaTV 301, DESTINY-PanTumor02.
- Interpretation of results within global health context.
- Discussion of immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs).
Main Results:
- Positive outcomes reported for locally advanced and advanced cervical cancer.
- Trials like INTERLACE, KEYNOTE-A18, BEATcc, innovaTV 301, and DESTINY-PanTumor02 show promise.
- Updated treatment algorithms are proposed based on trial findings.
Conclusions:
- 2023 trials are transforming cervical cancer management paradigms.
- Future research will focus on patients progressing after immune checkpoint inhibitors.
- Optimal selection, sequencing, and re-treatment strategies for novel agents are key.
More Related Videos
07:43Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
Published on: July 29, 2017
07:29Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
01:21Cancer Survival Analysis
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...